Upon evaluating the clinical development potential of these drug target genes, we found zinc supplementation and collagenase clostridium histolyticum might be potential therapeutics for sarcopenia by activating HP and inhibiting COL15A1, respectively. This evidence concerns the gene HP and sarcopenia.